银屑病生物制剂减量的国际共识:DR. Delphi研究
该研究采用国际改良eDelphi共识法,由62名全球皮肤科医生对11条生物制剂减量声明进行投票,共识标准为≥70%同意且<15%反对。两轮后所有声明达成共识,包括减量启动/终止标准及阿达木单抗、依那西普和乌司奴单抗的两步减量算法,IL-17和IL-23抑制剂减量也被认为可行但证据有限。
要点
- 全球皮肤科医生就银屑病生物制剂减量的启动与终止标准达成共识。
- 阿达木单抗、依那西普和乌司奴单抗可采用两步减量算法。
- IL-17和IL-23抑制剂减量被认为可行,但证据仍有限。
核心结论
- 全球皮肤科医生就成人银屑病患者生物制剂减量的时机与方法达成国际共识。
- 共识包括阿达木单抗、依那西普和乌司奴单抗的两步减量算法。
- IL-17和IL-23抑制剂减量被认为可行,但 underlying evidence 仍有限。
研究设计与样本
- 国际改良eDelphi共识研究,由国际指导委员会基于既往文献综述生成11条声明。
- 通过国际皮肤病学会分发邀请,62名来自欧洲、南美、亚洲、北美、非洲和澳大利亚的皮肤科医生完成eDelphi。
- 共识标准为≥70%同意且<15%反对,最多计划三轮投票和一次数字共识会议。
主要发现
- 第一轮后11条声明中9条达成共识,剩余2条修改后在第二轮达成共识。
- 参与者就何时考虑和启动/(停止)继续减量的标准达成一致。
- 参与者就阿达木单抗、依那西普和乌司奴单抗的两步减量算法达成一致。
关键数值与推荐
- 共识阈值:≥70%同意且<15%反对。
- 两步减量算法适用于阿达木单抗、依那西普和乌司奴单抗。
- IL-17和IL-23抑制剂的两步减量策略可考虑,但需等待更多科学证据。
临床怎么用
- 临床可参考共识标准决定银屑病生物制剂减量的启动与终止。
- 对阿达木单抗、依那西普和乌司奴单抗可按两步减量算法实施减量。
- 对IL-17和IL-23抑制剂减量需谨慎,因证据有限。
局限性
- IL-17和IL-23抑制剂减量的 underlying evidence 仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dose reduction (DR) of biologics for psoriasis is already applied in clinical practice but without clear guidelines, while dermatologists addressed the need for guidance. An international consensus may contribute to optimal implementation of biologic DR in clinical psoriasis practices. OBJECTIVES: This consensus study aims for international consensus on DR of biologics in adult patients with psoriasis among dermatologists worldwide. METHODS: An international, modified eDelphi consensus study was performed among dermatologists worldwide. A total of 11 statements on biologic DR were generated by the international steering committee, based on a previous literature review. Invitations were distributed via international dermatological societies. Participants rated their level of agreement per statement on a 9-point Likert scale. A maximum of three consensus rounds and one (digital) consensus meeting were expected. Statements reached consensus if ≥70% agreed and <15% disagreed; otherwise, statements were revised for a next consensus round. RESULTS: In total, 62 dermatologists from Europe, South America, Asia, North America, Africa and Australia completed the eDelphi. After one round, 9 out of 11 statements reached consensus. The remaining 2 statements were adapted and reached consensus in the second round. Participants agreed on criteria when to consider and initiate/(dis)continue DR and on a two-step DR algorithm for adalimumab, etanercept and ustekinumab. Participants agreed that this two-step DR strategy can also be considered for IL-17 and IL-23 inhibitors while awaiting more scientific evidence on DR of these newer biologics. CONCLUSIONS: Dermatologists worldwide reached consensus on when and how to initiate and (dis)continue DR of biologics, and on a two-step DR algorithm for adalimumab, etanercept and ustekinumab in adult patients with psoriasis. DR of IL-17 and IL-23 inhibitors was deemed feasible; however, underlying evidence is still limited. This first international consensus provides essential information for uptake and implementation of biologic DR for psoriasis on a global scale. Psoriasis is a chronic immune‐mediated disease causing erythematous, scaly, itchy patches interfering with a patient's quality of life. Psoriasis affects 2%–3% of the world population. Biologics like TNFα, IL‐12/23, IL‐17 and IL‐23 inhibitors (i) are highly effective treatments improving quality of life. However, as these drugs are prescribed in a fixed, registered dose, patients with controlled disease might be overtreated. Dose reduction (DR) of biologics might reduce avoidable overtreatment, reduce costs and possibly avoid adverse events. DR is already applied in daily practice but without clear (inter)national guidelines, while dermatologists addressed the need for more guidance in previous studies. This study aims for international consensus on DR of biologics in adult patients with psoriasis among dermatologists worldwide. In this international, modified eDelphi consensus study, a total of 62 dermatologists rated their level of agreement on a total of 11 statements on criteria for biologic DR. Statements reached consensus if ≥70% agreed and <15% disagreed; otherwise, statements were revised for a next voting round. It was expected that a maximum of three voting rounds and one (digital) consensus meeting was necessary to reach consensus on all statements. After two rounds, all statements reached consensus. Dermatologists agreed on criteria when to consider and initiate/(dis)continue DR, and on a two‐step DR algorithm for adalimumab, etanercept (TNFαi) and ustekinumab (IL‐12/23i). The two‐step DR strategy was also deemed feasible for IL‐17i and IL‐23i; however, underlying evidence remains limited. This international consensus contributes to a clearer and safer uptake of biologic DR in clinical practice globally.
引用
- van Riel CAM, Boehncke WH, Lambert JLW, et al. International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study. J Eur Acad Dermatol Venereol. 2026. PMID: 42012299. doi:10.1111/jdv.70447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。